- Home
- PEN
PEN
Penumbra Inc.
as of 01-06-2026 3:56pm EST
$315.93
+$0.93
+0.29%
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 12.2B | IPO Year: | 2015 |
| Target Price: | $332.40 | AVG Volume (30 days): | 439.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 4.14 | EPS Growth: | 367.34 |
| 52 Week Low/High: | $221.26 - $321.38 | Next Earning Date: | 02-17-2026 |
| Revenue: | $1,333,798,000 | Revenue Growth: | 14.61% |
| Revenue Growth (this year): | 16.77% | Revenue Growth (next year): | 14.12% |
AI-Powered PEN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 68.97%
68.97%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Penumbra Inc. (PEN)
Bose Arani
Sell
Director
PEN Dec 11, 2025
Avg Cost/Share
$308.72
Shares
15,000
Total Value
$4,632,292.11
Owned After
258,462
Roberts Johanna
Sell
EVP, Gen. Counsel & Secretary
PEN Dec 5, 2025
Avg Cost/Share
$300.13
Shares
300
Total Value
$90,039.00
Owned After
63,836
SEC Form 4
Grewal Harpreet
Sell
Director
PEN Dec 2, 2025
Avg Cost/Share
$292.98
Shares
100
Total Value
$29,298.00
Owned After
8,416
SEC Form 4
Roberts Johanna
Sell
EVP, Gen. Counsel & Secretary
PEN Dec 1, 2025
Avg Cost/Share
$295.29
Shares
600
Total Value
$176,966.11
Owned After
63,836
Bose Arani
Sell
Director
PEN Nov 21, 2025
Avg Cost/Share
$290.82
Shares
7,500
Total Value
$2,179,212.48
Owned After
258,462
Roberts Johanna
Sell
EVP, Gen. Counsel & Secretary
PEN Nov 10, 2025
Avg Cost/Share
$266.75
Shares
600
Total Value
$160,188.63
Owned After
63,836
Grewal Harpreet
Sell
Director
PEN Nov 4, 2025
Avg Cost/Share
$227.58
Shares
186
Total Value
$42,329.88
Owned After
8,416
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Bose Arani | PEN | Director | Dec 11, 2025 | Sell | $308.72 | 15,000 | $4,632,292.11 | 258,462 | |
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Dec 5, 2025 | Sell | $300.13 | 300 | $90,039.00 | 63,836 | |
| Grewal Harpreet | PEN | Director | Dec 2, 2025 | Sell | $292.98 | 100 | $29,298.00 | 8,416 | |
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Dec 1, 2025 | Sell | $295.29 | 600 | $176,966.11 | 63,836 | |
| Bose Arani | PEN | Director | Nov 21, 2025 | Sell | $290.82 | 7,500 | $2,179,212.48 | 258,462 | |
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Nov 10, 2025 | Sell | $266.75 | 600 | $160,188.63 | 63,836 | |
| Grewal Harpreet | PEN | Director | Nov 4, 2025 | Sell | $227.58 | 186 | $42,329.88 | 8,416 |
Latest Penumbra Inc. News
PEN Breaking Stock News: Dive into PEN Ticker-Specific Updates for Smart Investing
Compare PEN vs Leading Stocks
See how PEN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PEN Penumbra Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.